About the Journal

SKIN is a peer-reviewed, open access, online only journal dedicated to providing free access globally to disseminate dermatological knowledge. Authors retain copyright in their articles, licensing publication of their content through use of Creative Commons CCBY license. The journal does not charge fees, and is supported by the National Society for Cutaneous Medicine. 


Read More

Current Issue

Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

Published: 2022-11-16

In-Depth Reviews

A Review of the Risk of Cutaneous Squamous Cell Carcinoma after Vismodegib Therapy

Jenne Ingrassia, Jacqueline Maher, Abigail Cline

Page 453-457

Genomics and Precision Medicine

Interim Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes

Bruce Strober, Michael Bukhalo, April Armstrong, David Pariser, Leon Kircik, Sepideh Parhami, Paul Montgomery, Tobin Dickerson

Page 458-462

Research Letters

Severity of COVID-19 in Patients with Dermatomyositis: A Single Center, Retrospective Observational Cohort Study

Jessica Johnson, Amy Nowacki, Jatin Narang, Sarah Young, Anthony P. Fernandez

Page 497-501

Biologic Treatment of Psoriasis and Tuberculosis Testing: A Retrospective Analysis

Emma Batchelder, Mara Trifoi, Julie Hong, Steven Maczuga, Joslyn Kirby

Page 502-506

Support Group Utilization and Perspectives Among Hidradenitis Suppurativa Patients

Devea De, Terri Shih, Swetha Atluri, Denise Fixsen, Brindley Brooks, Jennifer Hsiao, Vivian Shi

Page 507-510

Brief Articles

Comorbidities, Healthcare Utilization, and Costs Associated With Alopecia Totalis and Alopecia Universalis in the United States

Carolyn Maskin; Arash Mostaghimi, Aster Meche, Markqayne Ray, Kavita Gandhi, David Gruben, Vanja Sikirica

Page 511-517

Adult-Onset Still’s Disease with an Atypical Cutaneous Manifestation

Shae Margulies, Nicole Nagrani, Paul Rodriguez-Waitkus, Lilia Correa-Selm

Page 518-522

A Case of Pityriasis Rosea Following Monkeypox Vaccination

Kaylin Beiter, Anna Swigert, Boni Elewski

Page 523-526

A Case of Pseudoverrucous Papules and Nodules in an Adult with Spinal Dysraphism

Gregory Ugoh, Caroline Crain, Brandon Goodwin

Page 531-533

Identifying Inflammatory Gene Expression Signatures for Skin and Soft Tissue Infections

Jennifer Yeh, Marcelo Pereira da Silva, Adam Raff, Ruth Foreman

Page 534-538

An Atypical Case of Granulomatosis with Polyangiitis with Cutaneous Features in a 19-year-old Female

Daniel Fischer, Rebeca Teplitz, Graham Litchman, Suzanne Sirota Rozenberg

Page 539-541

Aquagenic Urticaria in an Adolescent Following COVID-19 Vaccine

John Broderick, Thomas Selby, Julian Trevino

Page 542-545

Short Communications

Psoriasiform Eruption in an Immunocompromised Neurosyphilis Patient

Olivia Lawson, Collins Langley, Michael Davis

Page 546-548

SKINmages: Clinical Images in Dermatology

Flagellate Dermatitis following Shiitake Mushroom Consumption

Kevin Mai, Derrick Adams, Jung Li

Page 549-550

Anal Monkeypox Lesions

David Walton Crasto, Moises Lutwak, Eduardo Krajewski, Eduardo Weiss

Page 551-552

Successful Treatment of Cutaneous Siderosis with Pulsed Dye Laser

McKenzie A. Dirr, Alison M. Bailey, MD, Richard Marchell, MD

Page 553-555

Poster Presentations from FC22 Dermatology Conference®: Psoriasis

Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program

Neil Korman, Thierry Passeron, Kenneth Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata Kisa, Subhashis Banerjee, Diamant Thaçi

Page s46

Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel, April Armstrong, Richard Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Griffiths

Page s47

Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

Richard Warren, Howard Sofen, Shinichi Imafuku, Jacek Szepietowski, Andrew Blauvelt, Lynda Spelman, Jessica Toms, Alex Buck, Subhashis Banerjee, Alan Menter

Page s48

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials

Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joseph F Merola, Mark Lebwohl, Thomas Scharnitz, Kim Hoyt, Renata M Kisa, Subhashis Banerjee

Page s49

Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application

James Del Rosso, Scott Guenthner, Chih-ho Hong, John E Jett, Philip M Brown, David S Rubenstein, Stephen C Piscitelli, Stephen C Piscitelli

Page s50

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Pooled Efficacy from Three Phase 3 Trials

Linda Stein Gold, Mark Lebwohl, Robert Bissonnette, Bruce Strober, Anna M Tallman, Philip M Brown, Stephen C Piscitelli, David S Rubenstein

Page s51

Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)

Laura K Ferris, April W Armstrong, James Del Rosso, Zoe D Draelos, Melinda Gooderham, Mark Lebwohl, Kim A Papp, Jennifer Soung, Linda Stein Gold, David Krupa, Robert C Higham, Patrick Burnett, David R Berk

Page s57

Improving Patient Acceptability and Adherence in Psoriasis Treatment

Alyssa Curcio, Christina Kontzias, Steven R Feldman

Page s59

Evaluating treatment choice among patients with moderate or severe psoriasis in the United States

April W Armstrong, Sayeli Jayade, Sanika Rege, Namita Joshi, Vardhaman Patel, David Davidson, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Dipen Patel, Lauren Seigel

Page s60

Indirect comparison of the short-, mid-, and long-term efficacy of treatments for moderate to severe plaque psoriasis: a systematic review and network meta-analysis

April W Armstrong, Richard B Warren, Yichen Zhong, Joe Zhuo, Allie Cichewicz, Ananth Kadambi, Daniel R Junqueira, Tracy Westley, Renata Kisa, Carolin Daamen, Matthias Augustin

Page s61

Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials

Mark Lebwohl, April W Armstrong, Joseph F Merola, Alice B Gottlieb, Leah Davis, Braulio Gomez, Susanne Wiegratz, Nancy Cross, Bruce Strober

Page s64

Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial

Bruce Strober, Yayoi Tada, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard G Langley, Jonathan Barker, Maggie Wang, Veerle Vanvoorden, Balint Szilagyi, Valerie Ciaravino, Carle Paul

Page s65

Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials

Kenneth B Gordon, Richard G Langley, Richard B Warren, Yukari Okubo, David Rosmarin, Mark Lebwohl, Luke Peterson, Cynthia Madden, Dirk de Cuyper, Natalie Nunez Gomez, Diamant Thaçi

Page s66

Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials

Andrew Blauvelt, Linda Stein Gold, Melinda Gooderham, Bruce Strober, Andreas Pinter, Jose-Manuel Carrascosa, Paolo Gisondi, Jonathan Bleier, Cynthia Madden, Delphine Deherder, Natalie Nunez Gomez, Richard B Warren

Page s67

Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension

Diamant Thaçi, Ron Vender, Menno de Rie, Curdin Conrad, Jennifer Soung, Bruce Strober, Maggie Wang, Nancy Cross, Delphine Deherder, Natalie Nunez Gomez, Alice B Gottlieb

Page s68

Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials

D Thaçi, A Armstrong, M Lebwohl, A Blauvelt, C Paul, L Puig, M Wang, V Vanvoorden, C Madden, S Wiegratz, D Deherder, KB Gordon

Page s71

Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials

A Armstrong, RG Langley, KB Gordon, RB Warren, D Thaçi, L Stein Gold, L Peterson, C Madden, N Nunez Gomez, D de Cuyper, A Costanzo

Page s72

Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials

Andreas Pinter, Bruce Strober, David Rosmarin, Paolo Gisondi, Veerle Vanvoorden, Luke Peterson, Cynthia Madden, Dirk de Cuyper, Richard B Warren

Page s73

Atopic Dermatitis

Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis

Tiffany Mayo, April W Armstrong, Leon Kircik, Jonathan Silverberg, Andrew Blauvelt, Ben Esdalie, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew F Alexis

Page s74

Conjunctivitis in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial

Andreas Wollenberg, Marjolein de Bruin-Weller, Jacob P Thyssen, Lisa A Beck, Eric L Simpson, Shinichi Imafuku, Mark Boguniewicz, Azra Kurbasic, Lise Soldbro, Natacha Strange Vest, Petra Arlert, Amy S Paller

Page s75

Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials

Tiffany Mayo, April W Armstrong, Leon Kircik, Jonathan I Silverberg, Andrew Blauvelt, Ben Esdalie, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew F Alexis

Page s76

The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Amy S Paller, Jonathan I Silverberg, Chih-ho Hong, Michael Cork, Luis Puig, Petra Arlert, Azra Kurbasic, Lise Soldbro, Eric L Simpson

Page s77

3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis

Richard B Warren, Kristian Reich, Eric L Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Emilia Vacko, Melinda Gooderham, Mette Deleuran, Juan Francisco Silvestre, Stefan Weidinger, Andrew Blauvelt

Page s78

Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest

Kristian Reich, Eric L Simpson, Richard Langley, Richard B Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein de Bruin-Weller, Andrew Blauvelt

Page s79

Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial

Amy Paller, Adelaide A Hebert, John E Jett, Philip M Brown, David S Rubenstein, Stephen C Piscitelli

Page s80

Acne & Rosacea

An Expert Panel Questionnaire for Assessing Patient-Reported and Caregiver-Reported Outcomes in Acne Vulgaris

Hilary Baldwin, Emmy Graber, Richard G Fried, Evan A Rieder, Julie C Harper, Andrew F Alexis, Linda Stein Gold, Adelaide A Hebert, James Del Rosso, Leon Kircik, Ayman Grada, Siva Narayanan, Volker Koscielny, Ismail Kasujee

Page s81

Impact of acne on social functioning, emotional functioning, and activities of daily living among patients with moderate to severe non-nodular acne vulgaris administered sarecycline in real-world community practices across the U.S. (PROSES Study)

Richard G Fried, Evan A Rieder, Andrew F Alexis, Hilary Baldwin, Emmy Graber, Julie C Harper, Linda Stein Gold, Adelaide A Hebert, James Del Rosso, Leon Kircik, Ayman Grada, Siva Narayanan, Volker Koscielny, Ismail Kasujee

Page s82

Patient Reported Outcomes (PROs) and Investigator Global assessment (IGA) of Acne Vulgaris among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in real-world community practices across the U.S. (PROSES Study)

Emmy Graber, Hilary Baldwin, Julie C Harper, Linda Stein Gold, Ayman Grada, Andrew F Alexis, Adelaide A Hebert, Richard G Fried, Evan A Rieder, James Del Rosso, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Leon Kircik

Page s83

Efficacy and Safety of Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Polymeric Gel in Pediatric Participants with Acne

Lawrence F Eichenfield, Linda Stein Gold, Leon Kircik, William P Werschler, Kenneth Beer, Zoe D Draelos, Emil A Tanghetti, Kim Papp, Hilary Baldwin, Edward Lain, Neil Sadick, Eric Guenin

Page s85

Benefit of Topical Combination Therapy for Acne Treatment: Analysis of Effect Size Using Number Needed to Treat

Steven R Feldman, George Han, Valerie Callender, Leon Kircik, Linda Stein Gold, Neal Bhatia, Stephen K Tyring, Joshua Zeichner

Page s86

Efficacy Evaluation of a Dermocosmetic with Skin Repair Properties after Fractional Laser Surgery in Acne Scars

Qian Zhang, Dong Zhang, Li Wang, Rongli Zhang, Jingyi Wei, Lin Gao, Xianghua Zhang, Delphine Kerob, Zhongxing Zhang

Page s87

Skin Cancer

An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis

Neal Bhatia, April W Armstrong, Todd Schlesinger, Leon Kircik, Brian Berman, Mark Lebwohl, Darrell Rigel, Vishal A Patel, James Del Rosso, Ayman Grada, Siva Narayanan, Ismail Kasujee

Page s89

Non-Invasive Genomic Profiling of Pigmented Lesions – an Interim Registry Analysis

Greg Stevens, Burkhard Jansen, Terry Arnold, James Rock, Jennifer Wood, Mark Hyde, Loren Clarke

Page s90

Review of Efficacy, Cost, and Adherence of Field Therapies for Actinic Keratosis

Nathaniel Lampley III, Todd Schlesinger, Rachel Rigo, Anthony M Rossi

Page s91

A clinical impact study of dermatologists’ use of the 23- or 35-gene expression profile tests to guide surgical excision and enhance management plan confidence

Aaron S Farberg, Kelli Ahmed, Briana B Rackley, Jennifer J Siegel, Brooke H Russell, Jason H Rogers, Sarah J Kurley, Matthew S Goldberg

Page s99

How Mohs surgeons utilize prognostic testing for high-risk cutaneous squamous cell carcinoma (SCC): a clinical impact study

Sarah T Arron, Alison L Fitzgerald, Jennifer J Siegel, Anesh Prasai, Briana B Rackley, Sarah J Kurley, Brent Moody

Page s100

Alopecia

Impact of Disease History on the Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Brett King, Wilma Bergfeld, Pawel Brzewski, Özge Aşkin, Thierry Passeron, Simaran Randhawa, Ernest Law, Roger A Edwards, Robert Wolk, Samuel H Zwillich, Alexandre Lejeune

Page s101

Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Totalis and Alopecia Universalis: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Xingqi Zhang, Nina Magnolo, Masato Mizuashi, Natasha Mesinkovska, Jerry Shapiro, Fan Zhang, Urs Kerkmann, Ernest Law, Robert Wolk, Gregor Schaefer

Page s102

Pruritus & Prurigo Nodularis

Oral Nalbuphine Extended-Release Is Effective in Severe Prurigo Nodularis–Associated Pruritus: Results From a Phase 2b/3, Double-Blind, Placebo-Controlled Study

Sonja Ständer, Elke Weisshaar, Jennifer L Parish, Jacek C Szepietowski, Adam Reich, Neil J Korman, Enoch Bortey, Thomas R Sciascia

Page s103

A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Brian S Kim, Robert Bissonnette, Kristine Nograles, Catherine Munera, Nilam Shah, Alia Jebara, Joshua Cirulli, Joana Goncalves, Mark Lebwohl

Page s104

Seborrheic Dermatitis

Hyperhidrosis

Dermatopharmacology

Skin Health & Hygiene

Sun Exposure and Associated Risks in 17 Countries: Results from Europe Compared to Other Continents

T Passeron, B Dreno, S Puig, CL Goh, HY Kang, F LY, A Morita, J Ocampo Candiani, S Schalka, L Wei, C Le Floc’h, D Kerob, HW Lim, J Krutmann

Page s108

View All Issues